As UK biotech gains steam, Syn­cona launch­es new Treg play­er while Cam­bridge spin­out ex­pands Se­ries A

Since merg­ing with the pub­lic in­vest­ment firm BAC­IT two-plus years ago, Syn­cona has made steady head­way in the cell and gene ther­a­py space: It watched Au­to­lus bag an $150M IPO, jumped in­to a $116 mil­lion round for Free­line and cel­e­brat­ed the $800 mil­lion sale of Night­star, all the while groom­ing its port­fo­lio of star­tups in which it typ­i­cal­ly holds a ma­jor­i­ty stake.

Now the Lon­don-based VC firm — once an in­de­pen­dent sub­sidiary of the Well­come Trust — is un­veil­ing its next big act, square­ly fo­cused on en­gi­neer­ing reg­u­la­to­ry T cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER